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Abstract: The measurement of the cardiac troponins 
(cTn), cardiac troponin T (cTnT) and cardiac troponin 
I (cTnI) are integral to the management of patients with 
suspected acute coronary syndromes (ACS). Patients with-
out clear electrocardiographic evidence of myocardial 
infarction require measurement of cTnT or cTnI. It there-
fore follows that a rapid turnaround time (TAT) combined 
with the immediacy of results return which is achieved 
by point-of-care testing (POCT) offers a substantial clini-
cal benefit. Rapid results return plus immediate decision-
making should translate into improved patient flow and 
improved therapeutic decision-making. The development 
of high sensitivity troponin assays offer significant clini-
cal advantages. Diagnostic algorithms have been devised 
utilising very low cut-offs at first presentation and rapid 
sequential measurements based on admission and 3  h 
sampling, most recently with admission and 1 h sampling. 
Such troponin algorithms would be even more ideally 
suited to point-of-care testing as the TAT achieved by the 
diagnostic laboratory of typically 60 min corresponds to 
the sampling interval required by the clinician using the 
algorithm. However, the limits of detection and analytical 
imprecision required to utilise these algorithms is not yet 
met by any easy-to-use POCT systems.
Keywords: analytical performance; cardiac troponin I; 
cardiac troponin T; myocardial infarction; point-of-care 
testing.
Introduction
The role of cardiac biomarker testing using point-of-
care testing (POCT) has to be seen in the context of three 
factors. First, the changes that have occurred in the man-
agement strategy for patients presenting with suspected 
ischaemic heart disease. Second, the changing role of 
cardiac biomarker measurement in the diagnosis and 
management of patients with suspected acute coronary 
syndrome (ACS). Finally, the paradigm shift that has 
occurred following development of assays for the cardiac 
troponins (cTn) cardiac troponin T (cTnT) and cardiac tro-
ponin I (cTnI). Initially the diagnosis of acute myocardial 
infarction (AMI) was based on clinical assessment and the 
electrocardiogram (ECG). The role of cardiac biomarkers 
was recognised in the original World Health Organiza-
tion (WHO) definition of AMI but only for confirmation of 
diagnosis when definitive ECG changes were not present 
[1]. In addition, the diagnostic discriminant used was 
twice the upper reference limit of the biomarker in ques-
tion. In statistical terms this meant that the probability of 
a positive result occurring in a patient without AMI was 
very low, 0.0044%. Thus, the probability of a false posi-
tive diagnosis arising from biochemical testing was very 
small indeed. This expectation of a very low false positive 
rate from biochemical testing has had a profound impact 
when biochemical testing assumed a more central role.
Changing management strategies 
in patients with acute chest pain
The diagnosis of AMI in patients with chest pain has 
undergone a series of step changes. Initially it was con-
sidered that coronary artery was universally fatal and it 
was not until the observation by Herrick in 1912 that myo-
cardial infarction was considered to be survivable. There-
after however, management was supportive and active 
intervention was considered but not universally accepted. 
The demonstration that intracoronary thrombosis was the 
underlying pathophysiological basis of myocardial infarc-
tion led to a reappraisal. Strategies based on opening the 
coronary artery by thrombolysis and by acute catheterisa-
tion were investigated and have become standard of care. 
Indeed, cardiac catheterisation and stent placement form 
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the basis of current guidelines [2, 3]. The initial strategy of 
serial measurement of cardiac biomarkers on a daily basis 
served only to retrospectively confirm diagnosis. Interest 
developed in more rapid strategies partly to allow earlier 
identification of patients with AMI and also to identify 
patients without AMI who could be rapidly and safely dis-
charged from the hospital. This trend was largely driven 
by the development of chest pain units and recognition 
that the majority of patients presenting with chest pain 
did not have AMI. The economics of inappropriate admis-
sion of patients with chest pain where the final diagnosis 
excluded AMI was recognised combined with a desire not 
to discharge patients inappropriately. This was most well 
developed in the US [4]. Diagnosis based on rapid serial 
measurements of myoglobin, creatine kinase (CK) and its 
MB isoenzyme (creatine kinase myocardial band [CK-MB]) 
were developed including the concept of delta change. 
Initial developments in POCT mirrored this with develop-
ment of technologies, initially single analytes and subse-
quently panels of cytoplasmic markers. Measurement of 
cardiac biomarkers shifted from ancillary test to part of 
the strategy of patient assessment combined with clinical 
history and the ECG.
Troponin assays and the paradigm 
shift in the definition of myocardial 
infarction
The development of immunoassays for cardiac structural 
proteins specifically cTnI and cTnT led to a number of 
studies to evaluate the additional clinical value of cTn 
measurement. When compared with diagnosis utilising 
CK or CK-MB, cTn had two distinct advantages. First, they 
identified a subset of patients with an apparent diag-
nosis of unstable angina based on conventional criteria 
that had an adverse prognosis [5, 6]. Second, they were 
specific for myocardial injury in the presence of other 
elevations of CK or CK-MB. The net result was that tro-
ponin was viewed as a test specific for AMI and used for 
dichotomous classification of AMI/No AMI and gained 
wide acceptance.
There were two significant flaws with this approach. 
The measurement of cTn was being compared against 
diagnosis based on WHO criteria. This meant that in 
patients without definitive ECG changes, the comparative 
diagnostic gold standard was a CK-MB twice the upper ref-
erence limit, with the extremely low false positive rate as 
discussed above. When this is combined with the complete 
cardiospecificity of cTn, the radically improved clinical 
diagnostic sensitivity was unsurprising. The second flaw 
was the relative insensitivity of the troponin assay in use 
at that time. These assays were unable to detect troponin 
in normal individuals and only detected significant eleva-
tions largely occurring in patients with AMI.
In addition to the consistent detection of high-risk 
individuals missed by conventional cardiac enzymes, a 
series of studies demonstrated that the detection of an 
elevated troponin in patients considered to have unstable 
angina predicted the response to low molecular weight 
heparin [7], glycoprotein IIb/IIIa antagonists [8] and 
revascularisation procedures [9]. These clear advantages 
led to the widespread adoption of cTn as the cardiac bio-
marker of choice. The true paradigm shift came with a 
series of expert conferences [10] culminating in the redefi-
nition of myocardial infarction using cTnT and cTnI as the 
gold standard test for the detection of AMI [11, 12].
These changes were reflected in the evolution of 
POCT with the development of marker panels including 
cTn. The logic behind this was the concept of a tempo-
ral period of “troponin blindness”. Hence, cytoplasmic 
markers, typically myoglobin and CK-MB were combined 
with cTn [13]. The idea was that the cytoplasmic markers 
would be released early and provide diagnostic sensitiv-
ity whereas the cTn would be detected subsequently and 
provide specificity of diagnosis. In addition, POCT tests 
for cTnT [14] and cTnI [15] alone were developed and 
showed comparable diagnostic sensitivity with central 
laboratory testing (CLT) but with markedly improved 
turnaround time (TAT). The crucial component to recog-
nise at this point is that POCT was diagnostically equiva-
lent to CLT. Diagnostic and management pathways could 
therefore use POCT. The challenge was to demonstrate 
clinical utility.
POCT for rapid diagnosis in patients 
with chest pain to improve patient 
management – what is the evidence 
base for clinical effectiveness?
It is an article of faith that rapid provision of test results 
by POCT will improve patient flow, reduce costs and 
improve the patient experience. The differential diagno-
sis of patients presenting with chest pain would seem 
to be an ideal situation where this could be applied. 
The management pathways for patients with myocar-
dial infarction are well defined. Patients presenting 
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with characteristic changes on the ECG, ST elevation, 
are characterised as ST elevation myocardial infarction 
(STEMI) [3]. Management is by immediate revasculari-
sation ideally by coronary angiography and stent place-
ment or if this is not possible by thrombolysis followed 
by subsequent angiography. Patients without defini-
tive ECG changes require a more sophisticated workup 
involving biochemical testing. It is here that troponin 
measurement defines the subsequent management 
pathways. Patients with an acute troponin elevation 
are categorised as probable non-ST elevation myocar-
dial infarction (NSTEMI) and are managed according to 
current treatment guidelines [2]. One important part of 
this process is that in the majority of patients immediate 
catheterisation is not required and repeat biochemical 
testing to confirm the diagnosis can be performed. In 
patients presenting without definitive ECG changes only 
a minority will have a final diagnosis of NSTEMI and 
biochemical testing is the cornerstone of management 
[16]. It would therefore seem ideal that is performed by 
POCT.
Studies on POCT in patients presenting with chest 
pain/AMI have tended to be observational in nature. 
The definitive answer to whether or not POCT would be 
of value would be achieved by a randomised controlled 
trial. Data from the randomised controlled trials of POCT 
are summarised in Table 1. Although the results have not 
always been entirely consistent, the general trend is that 
POCT results in reduction in length of patient stay and 
improved throughput. However, it is a common finding 
in the studies that impact on length of stay is critically 
dependent on process of care. Indeed this was specifi-
cally commented on in two of the studies [18, 20]. In 
one comparison the length of stay in the participating 
six hospitals showed radically different results [25]. 
The economic consequences of cardiac POCT have been 
relatively less examined. The Randomised Assessment 
of Treatment using Panel Assay of Cardiac markers 
(RATPAC) trial included economic modelling and costing 
[21, 22]. They concluded that POCT was not cost-effective 
largely because the major savings made were in Emer-
gency Department (ED) length of stay (which is low cost) 
but there was an increase in admissions to the hospital 
and coronary care unit. In this trial there was statisti-
cally significant improvement in accuracy of diagnosis 
of patients with AMI which accounted for the increased 
Table 1: Clinical trials of point-of-care testing.
Type   Methodology   Cut off   Location   Outcome   Result   Author
Single centre RCT   Roche cTnT CLT 
vs. POCT
  0.2 μg/L   ED referrals 
to CCU
  Length of stay in 
pre-specified rule 
out subgroup
  Reduction of length of 
stay in POCT group
  Collinson et al. [17]
Single centre RCT   Stratus CS vs. 
Dimension RxL
  0.1 μg/L   ED   Time to treatment
Length of stay in 
the ED
  Reduced time to 
treatment
No reduction in ED stay
  Renaud et al. [18]
3 Centres prospective 
observational study
  Triage cardiac 
panel vs. 
Dimension RxL
  0.4 μg/L   ED   Retrospective 
review of diagnostic 
accuracy
Length of stay
  Improved diagnostic 
accuracy of multimarker 
strategy
Increased number 
of discharges <24 h 
compared with historical 
data
  Straface et al. [19]
2 Centre Cluster 
randomised 
controlled trial
  iStat vs. 
Beckman 
Coulter Accu I
  ns   ED   Length of ED stay   Not significant   Loten et al. [20]
6 Centre RCT   Stratus CS vs. 
Central Lab
  0.7 μg/L   ED   Discharges <4 h
Length of hospital 
stay
MACE
  Increased discharge <4 h 
with less admissions
MACE was equivalent in 
POCT and CLT groups
  Goodacre et al. 
[21, 22]
Cluster RCT   Roche cardiac 
reader
  0.1 μg/L   68 Rural 
primary care 
centres
  Clinical diagnosis   Improved diagnostic 
accuracy
  Tomonaga et al. 
[23]
Single centre RCT   AQT Flex vs. hs 
cTnT
  14 ng/L   ED   MACE at 3 months   No significant differences   Asha et al. [24]
RCT, randomised controlled trial; cTnT, cardiac troponin T; cTnI, cardiac troponin I; ED, emergency department; CCU, Coronary Care Unit; 
POCT, point-of-care testing; CLT, central laboratory testing; MACE, major adverse coronary events; ns, not stated.
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admissions. It is arguable that the improved diagnostic 
accuracy from POCT would offset the apparent minimal 
change in costs.
Evolution of diagnostic strategies 
for rapid diagnosis of patients 
presenting with chest pain 
unsuspected AMI – high sensitivity 
cardiac troponin assays
The recommended diagnostic strategy for patients pre-
senting with chest pain was to measure cardiac tro-
ponin on admission and 6 h later. This strategy reflected 
the diagnostic performance of cardiac troponin assays 
whether by POCT or CLT. However, there has been pro-
gressive improvement in the analytical performance of 
cardiac troponin assays culminating in the development 
of high sensitivity cardiac troponin measurement. This 
has been driven by two factors. First, all manufacturers 
work to improve assay performance on a regular basis. 
The objective is to improve analytical imprecision at the 
low end of the measuring range. For cTn measurement, 
an additional incentive has been a consequence of the 
redefinition of myocardial infarction in terms of troponin. 
In the first document proposing redefinition of myocardial 
infarction with cTn as the preferred cardiac biomarker it is 
specifically stated [11]
“Acceptable imprecision (coefficient of variation) at the 99th 
 percentile for each assay should be defined as <10%”.
Since when this was published none of the commercially 
available cTn assays met these criteria, there was pressure 
on the manufacturers to improve analytical sensitivity. 
Initially, assays met the imprecision goal but would only 
detect cTn in 10–20% of normal healthy individuals. These 
have been designated as contemporary sensitive assays. 
The ultimate goal has been to produce assays that would 
measure cTn in the majority of normal healthy individu-
als. A high sensitivity troponin assay has been defined by 
the International Federation of Clinical Chemists (IFCC) 
as one which will have an assay imprecision of less than 
10% at the 99th percentile of a reference population but 
also measure cTn in 50% or greater of a normal reference 
population [26]. In practice, this means that the analyti-
cal imprecision at the 99th percentile is considerably less 
than 10% and often in the range of 2–5%. High sensitivity 
cTn (hs-cTn) assays are now available from the majority of 
major manufacturers [27].
The first impact of introduction of hs-cTn was a 
realisation that the same diagnostic efficiency could be 
achieved by measurement at 3 h from admission as was 
currently obtained with 6  h measurement. Earlier tro-
ponin detection on switching from a less sensitive to a 
more sensitive assay has previously been observed with 
iterations of assay improvement, as would be expected 
[28]. Early detection of troponin elevation on introduction 
of high sensitivity troponin assays is reflected in recom-
mendations from formal assessment performed by health 
technology assessment bodies such as the National Insti-
tute for Health and Care Excellence (NICE) in the UK [29] 
as well guideline bodies such as The European Cardiac 
Society (ECS) which supported the use of measurement at 
admission and 3 h from admission [2].
The introduction of hs-cTn assays into routine clinical 
practice coincided with developments in the ED to explore 
possibilities for more rapid strategies for early categorisa-
tion of patients presenting with chest pain. This has been 
based around the development of accelerated diagnos-
tic protocols (ADP) for patients with chest pain utilising 
scoring systems and earlier measurement of cTn [30]. This 
has ultimately resulted in the development of diagnostic 
strategies based on admission measurement of cTn using 
very low diagnostic cut offs either close to or at the limit of 
detection of the assay combined with clinical features to 
facilitate early rule out of AMI [31]. In addition, very short 
timescale repeat testing (1–2  h from admission) together 
with calculation of the rate of change of troponin (often 
referred to as delta troponin) has been recommended for 
rule-in and rule-out strategies [2, 32]. The clinical expec-
tation therefore is that patients with suspected ACS are 
evaluated using high sensitivity high precision assays. 
Remember though that although hs assays yield equiva-
lent clinical performance, analytical agreement is limited 
and absolute values from one manufacturer are not the 
same as those from another. This is important in examin-
ing rapid rule-out algorithms.
There have also been predictable but explicable con-
fusions arising from the use of troponin as the gold stand-
ard and the development of hs troponin assays. The initial 
introduction of troponin was, arguably, oversold as a 
cardiac specific test for myocardial infarction. In the days 
of the WHO definition of AMI this was not a problem as cut 
offs were adopted that excluded minor troponin elevations 
that were, nevertheless, detectable even with the assays 
in use at the time [33, 34]. This situation was exacerbated 
when hs assays were introduced when troponin elevation 
due to myocardial injury in a range of clinical conditions 
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was detected. The concept of myocardial injury is recog-
nised in the current redefinition of myocardial infarction 
[35]. However, it must be remembered that troponin eleva-
tion, whatever the cause, predicts an adverse prognosis 
and that for this reason, troponin remains an excellent ED 
rule-out test as it identifies a low-risk group reliably.
POCT in the era of high sensitivity 
cardiac troponin assays
The provision of repeat testing by the central laboratory 
for admission and repeat measurement 1–2 h from admis-
sion is a significant logistic challenge and is not met by 
the majority of diagnostic laboratories. In addition, early 
studies of POCT suggest that it is the impact of having 
results within the timeframe of patient consultation that 
prompts management decisions [17]. It would therefore 
seem likely that provision of hs-cTn measurement by 
POCT is the ideal method to implement rapid diagnostic 
algorithms. Unfortunately, this is not yet met by any of the 
commercially available systems [36]. Comparable diag-
nostic efficiency combining a risk score with admission 
measurement by hs-cTn by the laboratory requires meas-
urement 3 h from admission when POCT is used [37]. To 
date, only one analytical system suitable for near patient 
testing has appropriate analytical sensitivity but it is more 
suitable to the emergency laboratory than the true POCT 
environment [38]. Comparable diagnostic sensitivity to 
hs-cTn measurement by the laboratory is not achieved for 
POCT until typically 6 h from admission.
A range of assays are in development utilising a range 
of novel techniques which promise to deliver compara-
ble analytical performance to hs-cTn measurement by 
the central laboratory when measured by POCT [39, 40]. 
There are already instruments close to routine clinical use 
delivering analytical performance comparable to labora-
tory hs-cTn measurement [41–43]. The challenge will be to 
validate these assays in appropriate clinical studies and 
ultimately by prospective randomised controlled trials.
Conclusions
Biomarker testing specifically the measurement of cTn 
dominates the management of patients with suspected 
ACS. Clinical trials performed during the early stages of 
POCT development when analytical sensitivity by POCT 
matched the central laboratory showed improvement in 
the TAT and shortening of ED stay. They also highlighted 
the importance of process in the decision-making and 
only demonstrated benefit when the POCT providing the 
analytical component was integrated within the decision-
making pathway. The switch to high sensitivity troponin 
and the use of very rapid rule-out protocols have there-
fore been a game changer. POCT now needs to not only 
match the analytical capability of laboratory methods for 
high sensitivity troponin but also be integrated within the 
decision matrix to demonstrate benefit. A further caveat 
remains. The ED environment remains a challenging one 
to ensure analytical quality matches that are produced by 
the central lab. In addition, as with hs assays that do not 
give numerically equivalent results, POCT may not agree 
with CLT and if two different types of troponins are meas-
ured, cTnI in the ED and cTnT in the central lab (or vice 
versa), there is potential for disaster.
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